HEMATOLOGY

Twenty-two days following transplantation, a patient with graft-versus-host disease presented with new symptoms.

Patients with high levels of amphiregulin appeared to be at a higher risk of early death from acute graft-versus-host-disease, signaling that it may be a predictive biomarker.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.

In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.

High antibody levels were observed in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA-1273 SARS CoV-2 vaccination.

Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone improved hematologic and organ responses after 18 months of follow-up in the phase 3 ANDROMEDA study.

Luspatercept-aamt for the treatment of anemia in adult patients with non-transfusion dependent beta thalassemia is on track to receive an FDA approval indication.

A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.

The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.

Ronald S. Go, MD, a hematology oncologist with the Mayo Clinic, discusses treating and diagnosing histiocytic neoplasms, a rare hematologic cancer.

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.

Complex challenges have arisen with classifying and treating hematologic malignancies in recent years, according to Jorge E. Cortes, MD.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.

Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.

Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.

Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.

Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.

Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.

During an interview, Yi-Bin Chen, MD, an investigator of the REACH trials, discussed acute and chronic graft-versus-host disease and treatment options.

The trial is designed to evaluate eltanexor monotherapy in high-risk MDS. It is recruiting in 8 separate states.

For older patients with acute lymphoblastic leukemia, traditional chemotherapy approaches have largely failed.

John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.

John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.